Recruiting

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(27 sites)

Argentina

Centro Oncologico Korben, Ciudad Autonoma Buenos Aires

Brazil

Hospital Araujo Jorge, Goiânia, Goiás

Hospital do Cancer de Pernambuco - HCP, Recife, Pernambuco

Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande do Sul

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, São Paulo, São Paulo

Canada

Sunnybrook Odette Cancer Centre, Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec

Jewish General Hospital, Montreal, Quebec

McGill University Health Center, Montreal, Quebec

Germany

Das Brustzentrum, Berlin

HELIOS Klinikum Berlin-Buch, Berlin

Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden, Dresden

Kliniken Essen-Mitte, Essen

Universitätsklinikum Heidelberg, Heidelberg

St. Vincenz-Krankenhaus GmbH Paderborn Frauen- und Kinderklinik St. Louise, Paderborn

HELIOS Klinikum Schwerin, Schwerin

South Korea

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Asan Medical Center., Seoul

Samsung Medical Center, Seoul

Spain

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

Hospital Clinic Barcelona, Barcelona

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Clinico Universitario de Salamanca, Salamanca

Hospital Universitario Virgen Macarena, Seville

Hospital Clínico Universitario de Valencia, Valencia